Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859962 · ClinicalTrials.gov registry record · Phase 2
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
A Phase 2 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01859962: Completed Phase 2 study, sponsored by Presidio Pharmaceuticals.
NCT01859962 is a Phase 2 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01859962, a Phase 2 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
Interventions
- DRUG Ribavirin
- DRUG Faldaprevir
- DRUG PPI-668
- DRUG BI 207127 Dose 1
- DRUG BI 207127 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01859962 record still lists
NCT01859962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.
NCT01859962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01859962 about?
NCT01859962 is a clinical study titled "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C". This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
What is the current status of trial NCT01859962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2013-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01859962?
The interventions under investigation include: Ribavirin (DRUG), Faldaprevir (DRUG), PPI-668 (DRUG), BI 207127 Dose 1 (DRUG), BI 207127 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT01859962?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01859962's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia